Table 2.

Comparison of Follow-up, Decompensation Events, Liver-related Outcomes and Adverse Effects Between Patients in Carvedilol (n = 25) and Propranolol Group (n = 23). Events Were Similar in Both Groups Except for Ascites, Which was More Common in patients Randomised to Propranolol.

Outcomes	Carvedilol Arm (n = 25)	Propranolol arm (n = 23)	P value
Duration of follow-up (in days)	1550 (480–2250)	1065 (500–1825)	0.535
Re-bleeding	6 (24%)	9 (39.13%)	0.259
Site of re-bleeding			0.673
•Esophageal varix	4 (66.67%)	7 (77.78%)
•Post EBL ulcer	3 (50%)	2 (22.22%)
Additional decompensation events
•New/worsening ascites	10 (40%)	16 (69.57%)	0.04
•HE	6 (24%)	8 (34.78%)	0.412
•HRS	6 (24%)	5 (21.74%)	1.0
•SBP	5 (20%)	5 (21.74%)	1.0
•HCC	1 (4%)	2 (8.7%)	0.601
•ACLF	2 (8%)	4 (17.39%)	0.407
Deaths	12 (48%)	12 (52.17%)	0.773
Heart rate achieved	62.08 ± 2.97	63.18 ± 3.67	0.262
Adverse effects
•Fatigue	9 (36%)	7 (30.43%)	0.683
•Hypotension	5 (20%)	5 (21.7%)	0.332
•Depression	1 (4%)	3 (13.04%)	0.117
Management of side effects
•Dose reduction	5 (20%)	6 (27.27%)	0.732
•Drug discontinuation	5 (20%)	5 (22.73%)	1.0

Data are presented as n (%) for qualitative variables and as mean ±SD for quantitative variables. List of abbreviation: ACLF, acute on chronic liver failure; EBL, endoscopic band ligation; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; HVPG, hepatic venous pressure gradient; SBP, spontaneous bacterial peritonitis.